A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (opens ClinicalTrials.gov)
- Sponsor
- EyeBiotech Ltd.
- Enrolment
- 33
- Started
- 2023-06-12
- Last update
- 2026-11-03
Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Interventions: Remigromig